Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Phase 2 Unknown 73 enrolled wang shusen

NaSingle-groupOpen-labelTreatment

Summary

The study is designed to explore the clinical benefit following treatment with tucidinosta in combination with metronomic capecitabine and endocrine therapy in patients with hormone receptor-positive, Her2-negative advanced breast cancer who have received CDK4/6 Inhibitor treatment.

Timeline

Start: 2022-10-03
Primary completion: 2024-04-01
Completion: 2025-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anastrozole	Other / unclassified	1 mg	Oral
Subject	Capecitabine	Small molecule	500 mg	Oral
Subject	Exemestane	Small molecule	25 mg	Oral
Subject	Fulvestrant	Small molecule	500 mg	Intramuscular
Subject	Letrozole	Other / unclassified	2.5 mg	Oral
Subject	Tucidinostat	Small molecule	20 mg	Oral

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Summary

Timeline

Drugs

Indications